Consolidated Balance Sheets - USD ($) $ in Thousands	Apr. 30, 2017	Apr. 30, 2016
Current assets:
Cash and cash equivalents	$ 30,950	$ 21,764
Research and development tax credit receivable	2,250	1,883
Grants receivable	297	356
Prepaid expenses and other current assets	751	668
Total current assets	34,248	24,671
Property and equipment, net	97	74
Total assets	34,345	24,745
Current liabilities:
Accounts payable	1,153	1,008
Accrued expenses	1,865	2,114
Due to related parties		127
Total current liabilities	3,018	3,249
Commitments and contingencies (Note 10)
Convertible Preferred Stock		58,608
Stockholders’ equity (deficit):
Ordinary Shares, $0.0016 par value Shares issued and outstanding: None at April 30, 2017 and 2,167,367 at April 30, 2016		3
Common stock, $0.001 par value Shares authorized: 100,000,000 at April 30, 2017 Shares issued and outstanding: 9,713,042 at April 30, 2017 and none at April 30, 2016	10
Additional paid-in capital	89,815	212
Accumulated deficit	(55,855)	(37,252)
Accumulated other comprehensive loss	(2,643)	(75)
Total stockholders’ equity (deficit)	31,327	(37,112)
Total liabilities and stockholders’ equity (deficit)	$ 34,345	24,745
Series B Convertible Preferred Stock [Member]
Current liabilities:
Convertible Preferred Stock		33,002
Series A Convertible Preferred Stock [Member]
Current liabilities:
Convertible Preferred Stock		$ 25,606